Data / Drug companies / A-S Medication Solutions
A-S Medication Solutions: 2,841 products in the FDA NDC directory, labeler code 50090
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
A-S Medication Solutions (labeler code 50090) lists 2,841 products in the FDA National Drug Code Directory, covering 537 finished drugs by generic name. By type: 2,622 prescription drugs, 204 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 27, 2026.
The request: Watch A-S Medication Solutions (FDA labeler code 50090): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 50090
- Products in commercial distribution
- 2,841
- Packages
- 5,223
- Finished drugs by generic name
- 537
- Prescription products
- 2,622
- Over the counter products
- 204
- Controlled substance products
- Schedule II 1, Schedule III 16, Schedule IV 52, Schedule V 11
- Started marketing in the last 12 months
- 30
- Products with a marketing end date set
- 16
- Earliest marketing start
- June 27, 1952
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 2,464 | 86.7% |
| New drug applications (NDA) | 150 | 5.3% |
| Over the counter monograph drugs | 99 | 3.5% |
| Biologics (BLA) | 61 | 2.1% |
| Authorized generics (NDA) | 53 | 1.9% |
| Other unapproved drugs | 14 | 0.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 2,622 | 92.3% |
| Over the counter drugs | 204 | 7.2% |
| Vaccines | 15 | 0.5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 982 | 34.6% |
| Tablet, film coated | 647 | 22.8% |
| Capsule | 250 | 8.8% |
| Tablet, extended release | 99 | 3.5% |
| Cream | 94 | 3.3% |
| Injection, solution | 75 | 2.6% |
| Solution | 60 | 2.1% |
| Capsule, delayed release | 49 | 1.7% |
| Powder, for suspension | 47 | 1.7% |
| Tablet, film coated, extended release | 46 | 1.6% |
| Tablet, coated | 43 | 1.5% |
| Solution/ drops | 39 | 1.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Oxybutynin chloride | 50090-8078 | Tablet | Generic drugs (ANDA) | April 27, 2026 |
| Rizafilm | 50090-8038 | Film | New drug applications (NDA) | April 27, 2026 |
| Dapagliflozin | 50090-7972 | Tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Dapagliflozin | 50090-7971 | Tablet, film coated | Generic drugs (ANDA) | April 6, 2026 |
| Tadalafil | 50090-8039 | Tablet, film coated | Generic drugs (ANDA) | February 15, 2026 |
| Etodolac | 50090-8176 | Tablet | Generic drugs (ANDA) | February 13, 2026 |
| Etodolac | 50090-8037 | Capsule | Generic drugs (ANDA) | February 6, 2026 |
| Clobetasol Propionate | 50090-8001 | Ointment | Generic drugs (ANDA) | February 1, 2026 |
| Liraglutide | 50090-8145 | Injection, solution | Generic drugs (ANDA) | January 22, 2026 |
| Trazodone Hydrochloride | 50090-8080 | Tablet | Generic drugs (ANDA) | January 22, 2026 |
| Trazodone Hydrochloride | 50090-8077 | Tablet | Generic drugs (ANDA) | January 22, 2026 |
| Trazodone Hydrochloride | 50090-7944 | Tablet | Generic drugs (ANDA) | January 22, 2026 |
| Trazodone Hydrochloride | 50090-7943 | Tablet | Generic drugs (ANDA) | January 22, 2026 |
| Azithromycin | 50090-8144 | Powder, for suspension | Generic drugs (ANDA) | January 16, 2026 |
| Ibuprofen | 50090-8142 | Tablet, film coated | Generic drugs (ANDA) | December 15, 2025 |
| Ibuprofen | 50090-8141 | Tablet, film coated | Generic drugs (ANDA) | December 15, 2025 |
| Ibuprofen | 50090-8138 | Tablet, film coated | Generic drugs (ANDA) | December 15, 2025 |
| Ibuprofen | 50090-8137 | Tablet, film coated | Generic drugs (ANDA) | December 15, 2025 |
| Celecoxib | 50090-8133 | Capsule | Generic drugs (ANDA) | December 15, 2025 |
| Ibuprofen | 50090-8124 | Tablet, film coated | Generic drugs (ANDA) | December 15, 2025 |
| Ibuprofen | 50090-8122 | Tablet, film coated | Generic drugs (ANDA) | December 15, 2025 |
| Pregabalin | 50090-7983 | Capsule | Generic drugs (ANDA) | December 15, 2025 |
| Rosuvastatin Calcium | 50090-7976 | Tablet | Generic drugs (ANDA) | December 15, 2025 |
| Rosuvastatin Calcium | 50090-7975 | Tablet | Generic drugs (ANDA) | December 15, 2025 |
| Rosuvastatin Calcium | 50090-7968 | Tablet | Generic drugs (ANDA) | December 15, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.